The FDA pathway controls almost everything. Medical device product liability sits at the intersection of Georgia state law, federal FDA regulation, and the learned intermediary doctrine. The viability of claims depends substantially on how the device was approved by the FDA, what theories are pleaded, and whether federal preemption under Riegel v. Medtronic applies.
| FDA approval pathway | Review intensity | <em>Riegel</em> preemption | Available state law claims |
|---|---|---|---|
| Premarket Approval (PMA) | Most rigorous; Class III high-risk devices | Yes; bars claims imposing duties beyond FDA requirements | Parallel claims only (state duty must match federal requirement) |
| 510(k) clearance | Substantial-equivalence review to predicate devices | Generally no preemption | Standard design defect, manufacturing defect, failure to warn |
| De Novo classification | Novel devices without predicate; intermediate review | Analysis is fact-specific | Variable; depends on FDA conditions imposed |
The FDA approval pathway determines preemption exposure #
Medical devices reach the U.S. market through three primary FDA pathways:
- Premarket Approval (PMA): The most rigorous pathway for Class III high-risk devices. Devices that received PMA are subject to federal preemption under Riegel v. Medtronic, Inc., 552 U.S. 312 (2008).
- 510(k) clearance: Devices substantially equivalent to existing devices receive 510(k) clearance through a less rigorous review. Devices cleared through 510(k) are generally not subject to Riegel preemption.
- De Novo classification: A pathway for novel devices that do not have predicate devices. Preemption analysis is more complex.
The preemption analysis is therefore not uniform across medical devices. A plaintiff’s first task is identifying the FDA approval pathway for the specific device.
PMA-approved devices face strong preemption defenses #
For PMA-approved devices, Riegel preemption blocks state law claims that would impose duties different from or in addition to federal requirements. This effectively bars:
- State law claims seeking to require warnings beyond FDA-approved labeling
- State law claims alleging design defects in features specifically approved by the FDA
- State law claims based on manufacturing methods specifically approved by the FDA
What remains available are “parallel claims” (state law claims based on the manufacturer’s failure to comply with the FDA-approved specifications). A plaintiff alleging that the device was manufactured in violation of the FDA-approved manufacturing process can proceed, because the state law duty parallels the federal requirement.
Practically, parallel claim plaintiffs must:
- Identify specific federal requirements the manufacturer violated
- Plead and prove the regulatory violation in detail
- Distinguish their claims from theories seeking duties beyond federal requirements
510(k) devices generally remain subject to standard product liability claims #
Devices cleared through the 510(k) process generally do not face Riegel preemption. The 510(k) process is a clearance based on substantial equivalence to predicate devices rather than rigorous safety and effectiveness review. State law claims proceed on standard product liability theories: design defect, manufacturing defect, failure to warn, all under Georgia’s framework.
The result is a structural difference: implanted devices that went through PMA face strong preemption defenses, while implanted devices that went through 510(k) face standard product liability exposure. Some major medical device cases turn on this distinction.
The learned intermediary doctrine modifies the failure-to-warn duty #
In medical device cases, the manufacturer’s duty to warn the patient is generally satisfied by adequately warning the prescribing or implanting physician. The doctrine reflects the structure of medical device distribution: physicians select, implant, or prescribe devices based on patient-specific considerations and are positioned to communicate risks.
The doctrine requires:
- Adequate manufacturer warnings to the physician through labeling, IFUs (instructions for use), and direct communications
- Physician knowledge or capability to convey risks to patients
- No misrepresentation or concealment from physicians
When manufacturer warnings to physicians were adequate, the learned intermediary defense protects against state law failure-to-warn claims. When warnings to physicians were inadequate, the defense fails.
Defective medical device cases fall into recurring categories #
| Device category | Common defect pattern |
|---|---|
| Orthopedic implants | Design or manufacturing defects in hip and knee replacements, metal-on-metal hip cases |
| Pelvic mesh products | Transvaginal mesh used in pelvic organ prolapse and stress urinary incontinence repair |
| Hernia mesh products | Mesh used in hernia repair, with adhesion or migration issues |
| Cardiac devices | Pacemakers, defibrillators, and stents with various defect patterns |
| Surgical instruments | Stapling devices, electrosurgical tools, similar instruments |
| IUDs and contraceptive devices | Migration or perforation |
| Dental implants | Design or fitness issues |
| Insulin pumps and similar delivery pumps | Delivery defects |
Most of these categories have produced multidistrict litigation in federal court consolidating cases from multiple jurisdictions.
Multidistrict litigation coordinates many medical device cases #
Defective medical device cases frequently consolidate in federal court through multidistrict litigation (MDL) procedures. The Judicial Panel on Multidistrict Litigation transfers cases involving the same device to a single federal district for coordinated pretrial proceedings. After MDL discovery and bellwether trials, cases generally return to their originating courts for trial (or settle).
Georgia plaintiffs in major medical device cases frequently find their cases transferred to MDL proceedings in other districts. Local Georgia counsel coordinate with national MDL counsel on case management and trial preparation.
Discovery in medical device cases produces detailed manufacturer files #
Medical device discovery generates manufacturer documentation including:
- FDA premarket approval submissions and correspondence
- Post-market surveillance data
- Manufacturer internal safety reports and risk assessments
- Field action reports and recall histories
- Customer complaint logs
- Internal medical safety officer reports
- Distribution and sales records
This documentation can establish manufacturer knowledge of risks over time and support failure-to-warn theories where warnings to physicians were inadequate. Documents showing prioritization of sales over safety can support punitive damages under O.C.G.A. § 51-12-5.1.
The SoL and repose apply, but identifying first sale can be difficult #
Georgia’s two-year statute of limitations under O.C.G.A. § 9-3-33 and the ten-year repose under § 51-1-11(b)(2) both apply to medical device cases. The repose runs from first sale of the device, but identifying the first sale date can be complex for implanted devices that were stored in inventory before implantation.
When an implanted device causes disease that emerges slowly (such as latent infection, malignancy, or autoimmune response attributed to the device), the long-latency disease exception under O.C.G.A. § 51-1-11(c) may preserve negligence claims beyond the ten-year window. The exception by its terms applies to disease or birth defect, not to all delayed complications, and the analysis is fact-specific to the device and the injury.
This article is for informational purposes only and does not constitute legal advice. Personal injury cases turn on specific facts and applicable law that vary by case. If you have been injured in Georgia and want to understand your legal options, consult a licensed Georgia personal injury attorney.